Tmunity Therapeutics is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo.
Tmunity Therapeutics Incorporated
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.tmunity.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address3020 Market Street Suite 535, PA,19104PhiladelphiaUnited States
3020 Market Street Suite 535, PA,19104
Philadelphia
United States
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/tmunity-therapeutics-incorporated” connections=”true” suffix=””]
In Jan 2016, Tmunity raised $10 Mn in equity financing from Penn Medicine, the academic medical center of the University of Pennsylvania (Penn), and Lilly Asia Ventures.